<DOC>
	<DOCNO>NCT00038727</DOCNO>
	<brief_summary>The Diabetes Prevention Program ( DPP ) multi-center trial examine ability intensive lifestyle metformin prevent delay development diabetes high risk population due presence impair glucose tolerance ( IGT ) . The DPP end early demonstrate lifestyle reduce diabetes onset 58 % metformin reduce diabetes onset 31 % . The DPPOS design take advantage scientifically clinically valuable DPP participant . This group participants nearly 50 % minority represent large IFG/IGT population ever study . Clinically important research question remain focus 1 ) durability prior DPP intervention , 2 ) determination clinical course precisely know new onset diabetes , particular regard microvascular disease , CVD risk factor atherosclerosis , 3 ) close examination topic men vs woman minority population .</brief_summary>
	<brief_title>Diabetes Prevention Program Outcomes Study</brief_title>
	<detailed_description>The current DPPOS Executive Summary protocol , well DPP protocol lifestyle manual publication available : http : //www.bsc.gwu.edu/dpp/index.htmlvdoc</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Participation volunteer DPP .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>DPP</keyword>
	<keyword>IGT</keyword>
	<keyword>Prediabetes</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Macrovascular disease</keyword>
	<keyword>Microvascular disease</keyword>
</DOC>